Feed CORT
CO

Corcept Therapeutics CORT NASDAQ · Healthcare · United States

$69.22 -5.10% -$3.72

Summary

68 / 100 · Bulios Score

What speaks for it

  • Out of every 100 USD of revenue, 17 USD is left as net profit.
  • Revenue grew by 24% a year over the last 3 years.
  • It holds more cash than debt: $98.7M against $8.99M.
  • It earns 17 USD a year on every 100 USD of invested capital.

What to watch

  • You pay 49.3 USD for 1 USD of yearly profit, a lot for its sector.
  • It missed profit estimates 4 times in the last 8 quarters.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Fairly priced
Bulios Fair Price
Fair Value Price today $69.22

By our assumptions the price matches the value of the business: the two differ by less than 10 %.

P/E today 49.3 52% higher
5-year average P/E 32.5
P/E today 49.3
Medical - Pharmaceuticals industry median

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

Today you pay 49.3 USD for 1 USD of yearly profit. Over the last five years it was 32.5 USD on average.

Valuation in detail

Is it growing?

Slowly

Revenue (USD)

Diluted EPS (USD)

  • Analyst estimate

Revenue grew by 17% a year over 5 years. Over the last 3 years it grew by 24% a year. Earnings per share fell by 2.0% a year over the last 3 years.

Growth in detail

Does it make money?

Very well

Where 100 USD of revenue goes

Net profit, industry median (Medical - Pharmaceuticals) 6.1 USD

Out of every 100 USD of revenue, 17 USD is left as net profit.

Profitability in detail

Is it financially healthy?

Yes

It could repay all its debt from a single year of free cash flow. It holds more cash than debt.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $132.8 is 92% above today's price. 54% of the analysts recommend buying.

Analysts in detail

What does it earn on?

By product

The company reports no revenue by product.

By region

The company reports no revenue by region.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy